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Electron microscopy (EM)The two major calcium (Ca2+) release channels on the sarco/endoplasmic reticulum (SR/ER) are inositol
1,4,5-trisphosphate and ryanodine receptors (IP3Rs and RyRs). They play versatile roles in essential cell signaling
processes, and abnormalities of these channels are associated with a variety of diseases. Structural information
on IP3Rs and RyRs determined using multiple techniques including X-ray crystallography, nuclear magnetic
resonance (NMR) spectroscopy and cryo-electronmicroscopy (EM), has signiﬁcantly advanced our understand-
ing of the mechanisms by which these Ca2+ release channels function under normal and pathophysiological
circumstances. In this review, structural advances on the understanding of the mechanisms of IP3R and RyR
function and dysfunction are summarized. This article is part of a Special Issue entitled: 13th European Symposium
on Calcium.
© 2014 Elsevier B.V. All rights reserved.1. Importance of calcium signaling by sarco/endoplasmic calcium
release channels
1.1. Critical roles of IP3Rs and RyRs for the normal cell functions
As a small and non-degradable intracellular messenger, the calcium
ion (Ca2+) is responsible for directing numerous intracellular signaling
pathways [1–3]. The versatility of Ca2+ signaling occurs via themodula-
tion of amplitude, duration and spatio-temporal patterning, enabling
the control of diverse and kinetically distinct cellular processes includ-
ing for example, cell proliferation, cell migration, gene transcription
and initiation of cell-death pathways [4, 5]. This versatility emerges
from a wide repertoire of signaling proteins called the Ca2+ signaling
toolkit [4, 5] which together orchestrate communicative changes in
compartmentalized Ca2+ levels. There are two classes of Ca2+ handling
macromolecules on the SR/ER membrane: 1) Ca2+ release channels
that liberate internally stored Ca2+ into the cytoplasm, and 2) Ca2+opean Symposium on Calcium.
RS Centre, 101 College Street,
x: +1 416 581 7564.
).pumps that move cytosolic Ca2+ back into the SR/ER. The release of
Ca2+ from the SR/ER occurs at minimal energy expenditure due to the
high Ca2+ concentration gradient maintained between the cytosol
and SR/ER lumen (i.e. cytosolic Ca2+ ~0.1–1 μM versus SR/ER luminal
Ca2+ ~1 mM), while reﬁlling of the SR/ER lumen is an energy demand-
ing process.
The twomajor families of Ca2+ release channels include the inositol
1,4,5-trisphosphate receptors (IP3Rs) and the ryanodine receptors
(RyRs). Molecular characterization of IP3Rs and RyRs has dramatically
improved our understanding of the bases for the regulation of SR/ER
Ca2+ signaling processes [6,7]. The IP3Rs and RyRs are transmembrane
protein cousins with similar functional characteristics. Although IP3Rs
absolutely require inositol 1,4,5-trisphosphate (IP3) for activation,
they can be considered Ca2+-induced Ca2+ release channels akin to
RyRs, since both IP3R and RyR require low Ca2+ levels for channel acti-
vation and are inactivated at high Ca2+ levels [8–10]. Three isoforms of
IP3Rs (IP3R1, IP3R2, and IP3R3) and RyRs (RyR1, RyR2, and RyR3) have
been identiﬁed inmammalian vertebrates [11]. In non-mammalian ver-
tebrates three isoforms of IP3Rs and two RyR isoforms (RyRα and RyRβ)
have been discovered [12, 13]. Remarkably, recent structural elucidation
of IP3Rs and RyRs revealed an analogous tetrameric overall architecture
and striking similarity in the activation mechanisms of these channels
(see below). Here, we review the structural properties of these channels
focusing on state-of-the-art X-ray crystallography, nuclear magnetic
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that have revealed crucial functional mechanisms for these proteins.1.2. IP3R related diseases
The roles of IP3Rs have been shown for ataxia, heart disease, exocrine
secretion deﬁcit, taste perception deﬁcit, several cancers and neurode-
generative diseases such as Alzheimer's disease (AD) and Huntington's
disease (HD) to name a few [14–23]. In this reviewwe focus on several
cancers, AD and HD. In cancer cells, Ca2+ signaling mechanisms are
frequently remodeled or deregulated [21,23,24]. Although alterations
in Ca2+ signaling may not be a requirement for the initiation of cancer,
altered Ca2+mobilization has been observed in breast and other cancer
cells, and known to contribute to tumor progression [21,23,25,26]. Cur-
rently little is known about what speciﬁc players in the Ca2+ signaling
tool kit contribute to the altered Ca2+ mobilization in cancer cells and
how Ca2+ signaling cross-talks with well-known cancer pathways
such as the Ras/Raf/MAPK pathway [27]. However, increasing numbers
of studies indicate the relevance of IP3Rs to cancer. Type 1 IP3R
(i.e. IP3R1) expression is reduced and type 3 IP3R (i.e. IP3R3) expression
is increased in human glioblastoma tissues, compared to normal human
brain [28]. Speciﬁc inhibition of IP3R3 by caffeine reduces themigration,
invasion and survival of glioblastoma cells [28]. Increased IP3R3 levels
are also observed in colorectal cancer [29]. Furthermore, multiple
B-cell lymphoma 2 (Bcl-2) family proteins, which have pro- and
anti-apoptotic functions, directly bind to different sites on IP3Rs
and elicit various effects on IP3R function [30–33], suggesting that IP3R
is an important hub for the action of Bcl-2 family proteins in various
physiological and pathological settings including tumor progression.
Interestingly, a recent paper has linked the Ras signaling pathway,
which is frequently deregulated in cancer [34], to the IP3R Ca2+ release
pathway. By comparing the parental human colorectal cancer cell line
harboring the K-Ras mutant allele (G13D) to an isogenic derivative in
which the mutated K-Ras allele is deleted, it was demonstrated that
oncogenic K-Ras inhibits IP3-induced Ca2+ release (IICR) from the ER
through remodeling of IP3R isoform composition [35]. Very recently, a
progressive study demonstrated a closer link between K-Ras and IP3R
showing that K-Ras4B is translocated from the plasma membrane to
ER upon phosphorylation of serine 181 (S181) by protein kinase C
(PKC) [36]. The translocated GTP-bound active form of K-Ras4B forms
a ternary complex with IP3R and Bcl-xL and promotes cell death [36],
indicating that IP3R is a novel effector of K-Ras4B.
Two common hallmarks of AD and HD are the aggregation of
misfolded proteins and dysregulated Ca2+ homeostasis [14,15].
Exaggerated IP3R-mediated Ca2+ release from ER has been reported in
non-neuronal cells from pre-symptomatic familial AD (FAD) patients,
neurons in ADmousemodels and Xenopus oocytes expressing presenilin
1 and 2 mutants [17,37–40]. The mechanism of the exaggerated Ca2+
release via IP3R is not fully understood. Onemodel is that FADmutations
in presenilins cause elevated ER Ca2+ levels, resulting in enhancement
of IP3R-mediated Ca2+ release [41–43]. Another hypothesis is that the
direct interaction of mutant presenilins with IP3R enhances Ca2+ re-
lease activity of IP3R [44, 45]. Further studieswill be needed for a deeper
understanding of the dysregulation of IP3R in the AD pathogenesis. HD
is an autosomal-dominant neurodegenerative disorder caused by
polyglutamine expansion in the amino-terminus of huntingtin (Htt)
[46]. It iswell known thatmutantHtt (mHtt) acquires toxic gain of func-
tions [47]. The direct interaction of mHtt with the C-terminal region of
IP3R1 was ﬁrst reported in 2003 [48]. The afﬁnity of mHtt to IP3R1 in-
creases when mHtt is associated with huntingtin-associated protein
1A (HAP1A) [48]. Moreover, mHtt, but not normal Htt, sensitizes IP3R1
activity in planar lipid bilayers [48]. Later, this direct interaction was
conﬁrmed using an unbiased high-throughput screening assay [49].
Recently, it was discovered that the direct interaction of IP3R1 with ER
stress chaperone protein GRP78 is impaired in HD R6/2 model mice,resulting in the dysregulation of IP3R1 signaling [50]. This line of studies
strongly suggests a role for IP3R in the HD pathogenesis.
1.3. RyR related diseases
Several cardiac and skeletal muscle disorders are associated with
hundreds of different RyR mutations. Most disease-associated muta-
tions are clustered in three regions on RyRs: 1) the N-terminal region
(i.e. residue range ~1–600), 2) the central region (i.e. residue range
~2100–2500) and 3) the C-terminal region (residue range ~3900–
5000). Mutations in RyR1, which are mainly found in the skeletal
muscle [51], have been associated with malignant hyperthermia (MH)
[52–55], central core disease (CCD) [56–58] and multiminicore disease
[59]. In RyR1, most MH mutations are located on the N-terminal and
central regions, whereas the mutations causing CCD are found in the
C-terminal region [60]. MH is characterized by increased temperature,
heart rate and rigidiﬁcation of themuscles usually triggered by the com-
bination of RyR1 mutations and an exposure to drugs such as volatile
anesthetic agents [61]. Dantrolene is clinically used to treat MH, and
while the molecular action mechanism of dantrolene remains elusive,
it is known that dantrolene decreases intracellular Ca2+ concentrations
by inhibiting RyR1 in the SR membrane [62–64].
RyR2 is predominantly expressed in cardiac myocytes [65,66], and
mutations in RyR2 have been linked to catecholaminergic polymorphic
ventricular tachycardia (CPVT) and arrhythmogenic right ventricular
dysplasia (ARVD) [67]. In cardiac muscle cells, RyR2 is activated when
luminal Ca2+ levels increase to a certain threshold, which is termed
store overload-induced Ca2+ release (SOICR); disease-associatedmuta-
tions in RyR2may lower the SOICR threshold [68, 69]. However, the pre-
cise molecular mechanisms that drive luminal Ca2+ sensing have been
elusive. Recently, it was proposed that the helix bundle crossing region
of RyR2 (i.e. the RyR2 gate) located in the predicted C-terminal inner
helix of RyR2 directly senses the luminal Ca2+ store, and residue
E4872 is essential for this sensing [70]. Consistent with this notion, a
single mutation (i.e. E4872A or E4782Q) in RyR2 completely abolished
luminal Ca2+ activation. Pharmacologically, therapeutic agents reduc-
ing RyR2 open time suppress Ca2+-triggered ventricular tachycardias
(VTs) [71–73]. Mouse hearts harboring an E4872Q mutation were also
shown to be protected against Ca2+-triggered VT by reducing RyR2
open time [70]. Therefore, the ‘RyR2 gate’ could be a potential target for
anti-arrhythmic therapeutics. Finally, although no disease-associated
mutations have been identiﬁed in RyR3 thus far, recent studies suggest
that RyR3 is related to neurodegenerative diseases such as Alzheimer's
disease [74,75].
It is not surprising that, as the key Ca2+ signaling regulators in
various tissues, both IP3R and RyR are implicated in human disease. To
understand how the malfunction of IP3R and RyR leads to different ab-
normalities in humans, we ought to elucidate the structure and function
relationship of those key players in Ca2+ signaling. In the past 15 years,
signiﬁcant progress has been made in our understanding of the three-
dimensional structure of IP3R and RyR, despite the large molecular
size. Below we will overview the ‘past and present’ of the structural
studies of the two important molecules in Ca2+ signaling.
2. High-resolution structures of IP3Rs and RyRs
2.1. The N-terminal domains of IP3Rs
At present, seven structural fragments of IP3Rs have been determined
by X-ray crystallography, and all the structures cover the N-terminal
region (NT) of IP3Rs [76–79]. TheNT of IP3Rs contains two functional do-
mains: 1) the suppressor domain (SD) and 2) the IP3-binding core (IBC);
together these domains bind IP3 and initiate channel channel gating
(Fig. 1A). Interestingly, the IBC is the minimal region required for IP3
binding, and IBC alone can bind to IP3 with extremely high afﬁnity; how-
ever, the IP3-binding afﬁnity of the entire NT encompassing both the SD
1982 M.-D. Seo et al. / Biochimica et Biophysica Acta 1853 (2015) 1980–1991and IBC is reduced more than twenty times, suggesting that the SD in-
hibits the IP3 binding to the IBC [80]. In addition to the suppressive role
of the SD, it is essential for IP3-induced channel gating, as a singlemuta-
tionwithin the SD (i.e.Y167) abolishes IP3-evoked Ca2+ releasewithout
affecting the IP3 binding afﬁnity [81]. Although the exact mechanism
how the IP3-binding induced signals are transmitted to the channel do-
main remains elusive, the critical loop in the SD containing Y167 is es-
sential for linking IP3 binding to channel gating.
The ﬁrst high-resolution structure of IP3Rs was the IBC of IP3R1
(i.e. residues 224–604) in complex with IP3 (i.e. PDB code 1N4K) [76].
The IBC contains a β-domain (IBC-β) and α-domain (IBC-α), adopting
a β-trefoil fold and an armadillo repeat fold, respectively (Fig. 1B). The
two domains are located almost perpendicular to each other, forming
an L-shaped structure of IBC. The cleft between IBC-β and IBC-α creates
the IP3 binding site. The crystal structure of the SD for IP3R1 (i.e. residues
1–223; PDB code 1XZZ) [77] is nearly identical to that for IP3R3
(i.e. residues 1–224; PDB code 3JRR) [81]. The SD forms a hammer-like
structure with ‘head’ and ‘arm’ subdomains. The ‘head’ subdomain of
the SD adopts a β-trefoil fold similar to IBC-β, and the ‘arm’ subdomain
of the SD consists of a helix-turn-helix conformation. However, the
IP3R1-SD and IP3R3-SD show different molecular surface properties
which may contribute to isoform-speciﬁc differences in IP3-binding
afﬁnity [82] (Fig. 1C).
Recently, two research groups independently determined crystal
structures of the NT of IP3R1 (i.e. residues 1–604). Lin et al. solved
both apo- and IP3-bound NT structures of rat IP3R1 at 3.8 Å resolution
from a single crystal grown in the presence of IP3 (i.e. PDB code 3T8S)
[79]. Subsequently, the NT structures of rat IP3R1 with all Cys residues
mutated to Ala (i.e. Cys-less form) at higher resolutions have been
determined. Importantly, the crystals were separately grown in the
absence and presence of IP3, and apo- and IP3-bound NT structures
were resolved to 3.0 Å for the apo-state (i.e. PDB code 3UJ4) and 3.6 Å
for IP3-bound state (i.e. PDB code 3UJ0) (Fig. 1D) [78]. The SD, IBC-β
and IBC-α in the NT structure form a triangular architecture with the
SD positioned behind the IP3-binding site. This arrangement suggests
that the SD allosterically inhibits the IP3 binding. Speciﬁcally, the SD
interacts with IBC-β and IBC-α, forming two discrete interfaces
(i.e. β-interface and α-interface). Hydrophobic interactions dominate
the short β-interface, stabilized by a salt bridge. The longer α-interface
consists of both hydrophobic and electrostatic interactions (Fig. 1D),
and plays an essential role in the inhibitory effects of the SD on IP3 bind-
ing [78]. The structural comparison of NTs in the absence and presence of
IP3 reveals the IP3 binding-induced conformational changes that are
essential for channel activation. The most signiﬁcant structural change
by IP3 binding is the domain reorientation between IBC-β and IBC-α,
resulting in partial closure of the IP3-binding cleft (Fig. 1E). Surprisingly,
the hydrophobic and electrostatic interactions forming the α-interface
are completely maintained after IP3 binding, while the β-interface is
disrupted resulting in a slight increase in the distance between the SD
and IBC-β. Additionally, the SD rotates towards the IBC, and the direction
of swing is nearly perpendicular to the closure of IBC. Ultimately, the
IP3-evoked conformational changes within NT cause the movement of
the critical loop in SD, especially the Y167 position, probably coupling
the SD reorientation to the activation of the channel domain [78,81].Fig. 1. (A) Domain architecture for IP3R1 and RyR1. The numbers on top of the domain diagram
complex with IP3 (PDB code 1N4K). Cartoon representation of the IBC-β (light green) and IBC-
surface of the SD from IP3R1 (PDB code 1XZZ) and IP3R3 (PDB code 3JRR). The acidic poc
(D) Superposed apo-NT (SD, blue; IBC-β, green; IBC-α, yellow, PDB code 3UJ4) and IP3-bou
Y167 in apo-NT and IP3-bound NT are depicted as sticks in squarewith dotted line. Close-up vie
line). Residues forming the interface are represented by sticks. (E) IP3-induced conformational c
red lettering (α11 and α12) represent the α-helices in apo-NT and IP3-bound NT, respective
magenta. Exon 3 is shownas orange, and theﬂexible loop replacing exon 3 in the RyR2-A delta e
are colored gray. (G) Cartoon representation of RyR2-A delta exon3 (PDB code 3QR5). The rescu
chains of disease-associated mutations located on inter-subunit interfaces and intra-subunit
of RyR1 phosphorylation domain (PDB code 4ERT). The two halves of two-fold symmetrical s
indicated by a black dotted line, and the position of the well-studied phosphorylation site S2842.2. The N-terminal and phosphorylation domains of RyRs
Theﬁrst high-resolution structures of RyRdetermined byX-ray crys-
tallography were of the ﬁrst ~210 residues making up the N-terminal
region (i.e. A domain) of RyR1 (i.e. PDB codes 3HSM and 3ILA) [83,84]
and RyR2 (i.e. PDB code 3IM5) [84], elucidating that the A domain
folds into β-trefoil core consisting of twelve β-strands and a single
α-helix (Fig. 1F). These initial structures revealed that a high frequency
of disease-related mutations for RyR1 (i.e. MH and CCD) and RyR2
(i.e. CPVT and ARVD) cluster in and around the loop connecting β8
and β9, termed the hot spot (HS) loop [83,84]. Recently, a mutant of
the RyR2-A associatedwith a severe form of CPVT has been investigated
[85]. The mutant consists of a deletion encompassing the entire third
exon of RyR2 encoding a 35-residue stretch made up of a β-strand
and an α-helix. Remarkably, rather than marked destabilization and
misfolding of this deletion mutant, the structural fold of the RyR2-A is
maintained by the insertion of a ﬂexible loop that is located immediate-
ly downstream of the deletion into the β-trefoil core (Fig. 1G; see also
Section 4).
The crystal structure of the larger N-terminal region (i.e. residues
1–559) of RyR1 has been successfully determined (i.e. PDB code 2XOA)
[86]. This larger construct encompasses three domains termed A, B and
C (Fig. 1A). Domains A and B fold into β-trefoil cores and domain C is
composed of a ﬁve-helix bundle (Fig. 1H). These three domains interact
with each other primarily via hydrophobic interactions, and 56different
disease-associated mutations from RyR1 and RyR2 are mapped onto
this structure [86]. To our surprise, the domain architecture found in
RyR1 is essentially identical to that previously reported for IP3R, despite
the low sequence similarity between the two proteins (17% identity).
More recently, the same group solved the crystal structures of 8
mutants of the RyR1-ABC that affect intra-subunit domain–domain
interfaces [87]. The location of these mutations and their impact on
RyR structure and function are discussed in Section 3 of this review.
Theﬁrst crystal structures outside theN-terminal region of RyR have
been independently solved by two groups [88,89]. The phosphorylation
domains from rabbit RyR1 (i.e. residues 2734–2940; PDB codes 4ERT
and 3RQR) [88,89], mouse RyR2 (i.e. residues 2699–2904; PDB code
4ETV) [89], human RyR3 (i.e. residues 2597–2800; PDB code 4ERV)
[89] and several disease-associated mutants [89] were determined
from 1.6 to 2.2 Å. In both RyR1 and RyR2, the domain consists of a
two-fold symmetrical structure in which each half is composed of two
α-helices, one or more short 310 helices and a C-terminal β-strand
(Fig. 1I). These symmetrical repeats are separated by a long and ﬂexible
loop (Fig. 1I), which contains the previously identiﬁed phosphorylation
target residues S2834 in RyR1 and S2808/S2814 in RyR2. The two halves
interact with one another with the β-strands forming a short
antiparallel β-sheet. In the corresponding domain of RyR3 the overall
symmetry is less conserved, where the ﬂexible loop is partially replaced
by an additional α-helix.
3. Combination of X-ray crystallography and EM
Because of the largemolecular size of IP3R and RyR, successful struc-
ture determination was made possible for relative small domains inrepresent the amino acid residues of rat IP3R1 and rabbit RyR1. (B) Structure of the IBC in
α (orange) are shown, and the IP3-coordinating residues are colored red. (C) Electrostatic
ket in IP3R3-SD and the equivalent region in IP3R1-SD are highlighted (white circle).
nd NT (magenta, PDB code 3UJ0) structures by overlaying the IBC-β. The side chains of
w of theα-interfaces in the apo- and IP3-bound states is also depicted (square with dotted
hange in the IBC is depicted with the same color code as panel (C). The black lettering and
ly. (F) Cartoon representation of wild-type RyR2-A (PDB code 3IM5). HS loop is colored
xon3 structure is indicated by a red dotted line. Side chains of disease-associatedmutations
e segment is shown in red. (H) Cartoon representation of RyR1-ABC (PDB code 2XOA). Side
interfaces (or buried) are colored red and blue, respectively. (I) Cartoon representation
tructure are shown in different colors (blue and yellow). Flexible phosphorylation loop is
3 is indicated. Side chains of disease-associated mutations are colored gray.
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many protein structure determinations in the past, proven to be
extremely powerful in the ﬁeld of structural biology. However, both
IP3R and RyR are a tetrameric transmembrane protein, and hence full
understanding of their structure–function relationships has to involveB
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While several crystal structures of IP3R and RyR fragments have now
emerged, a major task remains in piecing together these fragments into
full-length structures. To facilitate this effort, IP3R puriﬁed from rat cer-
ebellum [90] and RyR puriﬁed from rabbit skeletalmuscle [91]were fro-
zen in vitreous ice and analyzed by single-particle cryo-EM. Cryo-EM
maps of RyR1 have been determined by a number of laboratories [92,
93], and have consistently indicated that the full-length RyR tetramer
has amushroom-like appearancewith an enormous cytoplasmic region
sitting on top of a transmembrane domain (Fig. 2). The highest resolu-
tion cryo-EMmapof RyR in a closed conformationwas initially reported
at 9.6 Å [92], but later revised to be 12 Å based on adopting the “gold-
standard” approach [94]. Samso et al. also determined cryo-EM struc-
tures of RyR at lower resolution in the open- and closed-channel states,
suggesting that channel activity is likely linked to allosteric conforma-
tional changes within the full-length structure [93]. Recently, new
cryo-EM structures of RyR1 with higher resolutions (up to 4.8 Å) were
deposited in the Electron Microscopy Data Bank (EMDB codes 2751,
2752, 6106 and 6107).
In contrast, previously determined cryo-EM maps of IP3R have re-
vealed various shapes with little resemblance to each other. Theseinconsistencies are likely due to inherent ﬂexibility and heterogeneity
of samples prepared by the different research groups. Nonetheless, a
cryo-EMmapof the IP3R tetramer in a closed conformationwas obtained
by Ludtke et al. in 2011 [95], and its relevance was conﬁrmed through
numerous methods including tilt-pair validation [96]. This cryo-EM
structure revealed a height for IP3R of ~160 Å, nearly identical to RyR
with a smaller cytoplasmic region resting on the transmembrane domain
(Fig. 2). The resolution of the IP3R structurewas initially reported as 10 Å,
but was revaluated to be 14–17 Å [96], partly due to higher variances
detected in the internal architecture of the cytoplasmic region compared
to the solvent-exposed exterior and transmembrane regions.
3.2. Docking of crystal structures onto EM maps
Determination of cryo-EM maps of IP3R and RyR at a nanometer-
level resolution has provided opportunities to perform rigid-body
docking of crystal structures of the IP3R and RyR fragments in order to
produce quasi fully-assembled models. Computational docking pro-
grams, such as SITUS [97], were used to position IP3R1-NT [78] and
RyR1-ABC [86] near the top of their respective mushroom-shaped
cytoplasmic structures, with the ‘arm’-motifs of IP3R1-SD and RyR1-A
pointing towards the inner core of the structure (Fig. 2A). Interestingly,
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domains, RyR-A, -B and -C, to be independently docked into the
same positions [86]; however, similar attempts to ﬁt the smaller RyR-
phosphorylation domains resulted in ambiguous positions within the
clamp region (Fig. 2C, D) [88,89]. For both IP3R and RyR, four NT/ABC
molecules form a ring around the four-fold symmetry axis of the full-
length structures [78,86]. These quaternary arrangements suggest that
the ‘hot-spot’ loop of RyR-A [83] and the equivalent loop of IP3R-SD
are involved in creating the inter-subunit interfaces by interacting
with ﬂexible loops of RyR-B and IP3R-IBC-β from adjacent subunits,
respectively.
Comparison of quasi-atomic models of IP3R and RyR produced from
combining crystal structures and cryo-EMmaps have revealed structur-
al and functional similarities between the two channels. First, although
the cytoplasmic region of RyR is considerably larger than IP3R, the rela-
tive positions of N-terminal NT/ABC regions are virtually identical with
respect to the location of the transmembrane channel regions of these
receptors [78]. This is likely a reﬂection of crucial roles played by the
N-terminal region and transmembrane domain in forming functional
tetramers of IP3R and RyR, likely through a common mechanism. It
is noteworthy that the ability of the isolated NT regions of IP3R
and RyR1, 2 and 3 to oligomerize has been recently demonstrated
[98–100]. Remarkably, it was also shown that the RyR-A could be func-
tionally substitutedwith the IP3R-SD and the transmembrane domain of
IP3R could be replaced with the transmembrane domain of RyR in
chimeric proteins which maintained an ability to function as receptor
channels [78].
The common distance (~70 Å) between the N-terminal regions and
transmembrane domainmay suggest that these proteins share a similar
allosteric mechanism of regulating the channel activity through events
such as Ca2+/ligand-induced conformational changes in the NT/ABC
regions. Since the ‘arm’-motifs of RyR-A and IP3R-SD reside in these
inner core spaces, any conformational changes and/or alternate splicing
in this region, known to occur in IP3R for example, are likely to have
signiﬁcant impact on the allosteric regulation of these Ca2+ release
channels.
3.3. Disease-associated mutations in three-dimensional structures of RyRs
The crystal structure of the RyR1-ABC and the docking model of
RyR1-ABC in the cryo-EM map have provided new insights into the
effect of disease-associated mutations on the three-dimensional struc-
tures of RyRs [86]. The mapping of ﬁfty-six disease-associated muta-
tions (i.e. 33 mutations from RyR1 and 23 mutations from RyR2) onto
the RyR1-ABC structure clearly shows that most of these mutations
are positioned at the intra-subunit interfaces within the ABC domain
or inter-subunit interfaces between adjacent ABC subunits in the
docking model (Fig. 1H).
The inter-subunit interface between domain A comprised mainly of
residues from the HS loop and domain B comprised mainly of residues
from two ﬂexible loops is the site of 19 disease-associated mutations.
Another inter-subunit interface that is concentrated with mutations
lies between domain A and electron-dense columns which extend
towards the transmembrane domains [86]. Considering the high fre-
quency of disease-associated mutations found at the inter- and intra-
subunit interfaces, destabilization of these interfaces likely facilitates
the movement of individual domains, resulting in dysfunctional open
probabilities. Indeed, docking studies of RyR1-ABC into the open- and
closed-state cryo-EM maps of RyR have revealed that the inter-subunit
distance between domain A and domain B of neighboring subunits
increases by ~7 Å in the open state compared to that in the closed state
[87,101]. The conformational changes within N-terminal regions of RyR
between open and closed states are also supported by ﬂuorescence
resonance energy transfer (FRET) analysis [102]. These data imply
that widening of inter-subunit gaps and perturbation of inter-subunit
contacts are associated with channel opening.Crystal structures of disease-associated mutants of RyR1-ABC have
also revealed that buried mutations can have propagative effects on
inter-subunit interfaces [87]. For example,mutations at buried positions
L14R and G249R (i.e. PDB codes 4I7I and 4I1E, respectively) seem
to alter the inter-subunit interfaces by displacing the neighboring
side chains in loop regions via the introduction of bulky charged side
chains (Fig. 3A). Perturbations of RyR1-ABC structures by salt-bridge
mutations at the domain A:C intra-subunit interface (i.e. R45C, D61N
and R402G; PDB codes 4I6I, 4I3N and 4I37, respectively) also cause
inter-subunit orientation changes. Thus, a single mutation can result
in long-range structural changes which affect inter-subunit interfaces
(Fig. 3B). Lastly, some mutations at the intra-subunit A–B–C interface
(i.e. C36R, V219I and I404M; PDB codes 4I0Y, 4I8Mand 4I2S, respectively)
do not induce large structural changes, but lower the thermal stabilities,
suggesting that at any given time a larger fraction of unfolded states
would be accessed by these mutants. Together, these results suggest
that direct or indirect perturbations of inter-subunit interfaces between
RyR1-ABCs are common mechanisms of dysfunction for this class of
receptor Ca2+ channels.
Recently, crystal structures of the wild-type RyR2-ABC (i.e. residues
1–547 of mouse RyR2; PDB code 4L4H) and R420Q mutated RyR2-ABC
(i.e. PDB code 4L4I) which have been linked to CPVT were solved [103,
104]. The overall domain orientation of RyR2-ABC is similar to that
of RyR1-ABC, but the pattern of ionic pair stabilizing the structure is
different. RyR1-ABC has an ionic pair network formed by four residues
(i.e. R283–D61–R402–E40). In RyR2-ABC, however, only the R298–D61
ionic pair is maintained, and a chloride ion interacts with the three
charged residues R420, R298 and R276. The R420Q RyR2-ABC structure
shows no density for this chloride ion, thus breaking the charged link
between domains B and C (Fig. 3C) and causing domain reorientation
between domains A/B and C.
Eleven disease-associated mutations are found in the structure of
the RyR1 phosphorylation domain, and they are divided into three
groups [89]. The seven mutations in the ﬁrst group are located
near the S2843 phosphorylation site (i.e. R2840W, S2843P, E2764K,
S2776M, S2776F, L2785V and T2787S). The second group contains
three mutations which are located on the opposite face of the ﬁrst
group (i.e. R2939S, R2939K and E2880K), and the last group contains
the L2867G mutation which targets a buried residue. Most mutants
have a minimal effect on the thermal stability except for L2867G,
which also failed to crystallize. The structural integrity of the several
mutants of which crystal structures were solved remains intact [89].
The crystal structures of those mutants reveal that disease mutations
can alter the surface charge (i.e. E2764K, PDB code 4ETT), disrupt the
hydrogen bond network, induce loop rearrangement (i.e. S2776M,
PDB code 4ESU), and disrupt salt bridges, hydrogen bonds, and van
der Waals contacts, resulting in increased ﬂexibility (i.e. R2939S, PDB
code 4ETU) (Fig. 3D).
More recently, the relationships between disease-associated muta-
tions of RyR1 and calmodulin (CaM) binding were investigated by
isothermal titration calorimetry (ITC) [105]. Several genetic diseases
are often related with an increasing sensitivity of RyRs to Ca2+, and
the sensitivity of RyRs can be ﬁne-tuned by many accessory proteins,
such as CaM [106]. Two disease mutations are located on the third
CaM-binding domains of RyR1 termed CaMBD3 (i.e. residues 4295–
4325). The R4325Dmutation is associated with CCD andmultiminicore
disease and a duplication mutation of the Leu-Arg-Arg sequence
(i.e. L4319–R4320–R4321) has been linked to MH by increasing levels
of creatine kinase [107]. Both these disease-associated mutations in
CaMBD3 of RyR1 directly affect the binding between RyR1 and CaM in
both Ca2+-free and Ca2+-bound states.
4. NMR spectroscopy of IP3R and RyRs
While the crystal structures have provided most of the static struc-
tural pictures of the enormous cytosolic domains within RyRs and
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Fig. 3.Disease-associatedmutations in the high-resolution structures of RyRs. Superposition of thewild-type RyR1-ABC structure (gray, PDB code 2XOA) andmutant structures for (A, B).
Crystal structures of RyR1-ABCmutants at buried positions (A) andmutants affecting inter-domain ionic pairs (B) are shown, and themutated residues are depicted as sticks. Eachmutant
structure is colored light pink (G249R, PDB code 4I1E), yellow (L14R, PDB code 4I7I), blue (R45C, PDB code 4I6I), light green (D61N, PDB code 4I3N) and pink (R402G, PDB code 4I37),
respectively. (C) Structures of wild-type RyR2-ABC (red, PDB code 4L4H) and R420Q mutant (cyan, PDB code 4L4I). The residues forming the ionic pair network via chloride ion (gray
sphere) in wild-type and the corresponding residues in R420Q mutant are shown as sticks. (D) Crystal structure of the phosphorylation domain of RyR1 (white, PDB code 4ERT) is
superposedon the structures of diseasemutants (E2764K, orange, PDB code 4ETT; S2776M,magenta, PDB code 4ESU; R2939S, brown, PDB code 4ETU), respectively. Themutated residues
and neighboring residues are depicted as sticks.
1986 M.-D. Seo et al. / Biochimica et Biophysica Acta 1853 (2015) 1980–1991IP3Rs (see above), solution NMR experiments have revealed dynamic
information regarding the structures of these protein domains, vital
for understanding how conformational changes mediate channel func-
tion in health and disease. This section reviews the available solution
NMR data of the IP3R and RyR N-terminal cytosolic domains.4.1. Conformational exchange and binding in the IP3R N-terminal domains
Even prior to the collective elucidation of the crystal structures of the
IP3R1 N-terminal domains (i.e. SD and IBC) revealing relative orienta-
tion changes with and without the IP3 binding [78,79] (see Section 2),
1987M.-D. Seo et al. / Biochimica et Biophysica Acta 1853 (2015) 1980–1991solution NMR showed that conformational exchange exists in these do-
mains, and remarkably, the structural switching is inﬂuenced by the
presence of the IP3 [108]. Speciﬁcally, solution NMR of the IBC in the ab-
sence of any ligand demonstrated 1H–15N-HSQC spectral (i.e. reporting
on the polypeptide backbone conformation) peak broadening and in-
tensity heterogeneity; however, when IP3 was added to the samples,
the IBC spectrum dramatically improved as a single conformation was
stabilized [108]. The solution NMR 1H–15N-HSQC spectrum of the SD
was in good agreement with a well-folded domain and did not change
in response to IP3. Nevertheless, NMR analysis of the full NT (i.e. SD
together with the IBC) exhibited severe peak broadening both in the
presence and absence of the IP3 ligand, beyond what is expected
for the increased size of the NT compared to the separate IBC and SD;
moreover, this broadening is indicative of the presence of different
conformational sub-states within the IP3R1-NT irrespective of IP3 levels
[108]. Overall, this solution data showed that IP3 binding shifts the con-
formational equilibrium of the IP3R1-NTs towards a compacted state
and that this cytosolic region is in a dynamic conformational exchange
at all times.
The initial structural changes (i.e. closing of the clam-like IBC structure
and SD rotation towards the IBC) are believed to trigger the allostery re-
quired for gating of the channel pore (see Section 2) [78]. Precisely how
the gating works is still a matter of debate and requires more structural
studies. Nonetheless, solution NMR experiments have provided a few
possibilities for linking these initial structural changes to downstream
gating. It was reported that Y167 of IP3R1 (i.e. W168 in IP3R3) in the
SD is required for Ca2+ channel activity (see Section 2) [109]. Further,
a C-terminal fragment of IP3R1 corresponding to residues 2418–2749
was suggested to inter-molecularly interact (i.e. between adjacent sub-
units)with theNT of these receptors, thereby linking structural changes
in the cytosolic domains with pore regulation in the transmembrane
domains [110]. Additionally, mutations in the loop region between
transmembrane segments 4 and 5 (i.e.M4–M5 region, residues 2418–
2437) have been shown to abolish channel activity [111]. Solution,
NMR titrations of the IP3R3-SD with two M4–M5 linker peptides
covering residues 2356–2365 (i.e. 2418–2437 in IP3R1) showed peak
broadening indicative of relatively transient binding; however, among
the three residues which showed N20% peak intensity differences
(i.e. E19, W168 and S218) in the presence of the peptides was W168
(i.e. Y167 in IP3R1), previously shown to be essential for channel activa-
tion [81,109]. Taken together, these solution data suggest that structural
changes in the IP3R-SD may be linked to channel gating interactions
with the M4–M5 transmembrane region. Further structural work is
required to determine the relevance of these weak interactions and a
fuller picture bywhichN-terminal allostery is linked to transmembrane
gating of the pore.
4.2. Regulation of IP3R1-NTs by CaBP1
It has been well established that IP3R activity can be positively and
negatively modulated by Ca2+ levels [9,112–114]. In addition to
the large body of evidence demonstrating activity modulation by the
promiscuous and ubiquitous calmodulin [115–126], Ca2+ binding
protein-1 (CaBP1) can regulate these receptor channels [127,128]. Solu-
tion NMR experiments were successful at linking these observations by
demonstrating that direct interactions between Ca2+-bound CaBP1 and
residues on the IP3R1-NT (i.e. residues 1–587) take place [129]. Interest-
ingly, the data showed that the CaBP1-binding site of IP3R involves both
the SD and the IBC since 1H–15N-HSQC spectra of Ca2+-CaBP1 failed to
exhibit any perturbations in response to separate addition of unlabelled
SD or IBC proteins [129]. Additionally, the NMR spectral changes
were localized to the C-terminal domain of CaBP1, suggesting that the
N-lobe does not interact with the IP3R1-NT, and Ca2+-free CaBP1 ex-
hibited at least 10-fold less afﬁnity compared to Ca2+-loaded for the
IP3R1-NT, consistent with a vital role for cytosolic Ca2+ levels in medi-
ating this binding [129]. More recently, using a clever approach ofsite-directed labeling of the IP3R1-NT [i.e. rationalized from the recent
full-length NT structures (see Section 2)] with paramagnetic spin tags,
residues V101, L104 and V162 on the C-lobe of CaBP1 which showed
broadened 1H–13C-methyl resonanceswere found to interactwith a hy-
drophobic cluster on the IBC-β [100]. While no residues of interaction
were identiﬁed on the SD using this methodology, NMR-data-guided
docking of the Ca2+-bound CaBP1 C-lobe revealed a close apposition
to the interface between the SD and the IBC, as originally suggested
[100,129].4.3. Effect of disease-associated mutations on RyR1-A conformation
Theﬁrst crystal structure of the RyR1-A (i.e. residues 1–214) demon-
strated that as many as 8 mutations associated with MH and CCD are
localized on the HS loop between β8 and β9 of domain A; further,
RyR2 disease mutations associated with cardiomyocyte arrhythmias
and tachycardias also map to this HS-loop (see Section 2) [83,130,
131]. Solution NMR was used to probe the effect of disease-associated
mutations on the HS-loop structure. It became apparent that for some
mutants (i.e.R164C) veryminimal structural perturbations occurwithin
domain A, while other mutations (i.e. R178C) resulted in localized
changes within the loop and surrounding region in the absence of any
global structural or stability disruption [83]. Together, the data suggest
that different RyR1 mutations may manifest disease through different
mechanisms of channel dysfunction.4.4. Elucidation of a dynamic hidden arm-domain helix in the RyR2-A
The arm region of RyR-A varies considerably among three types of
RyRs. Compared to the IP3R1-SD containing a helix–loop–helix arm do-
main, RyR1 and RyR3 have a deletion in the sequence responsible for
fully constituting this motif, while the RyR2 homolog has a 12-residue
insertion in this stretch more similar to the IP3Rs (Fig. 4A and B). The
RyR1-A and RyR1-ABC crystal structures exhibit low electron density
in this arm domain region, indicative of the unstable structural fold
[83,86]. Surprisingly, however, a crystal structure of the RyR2-A also
shows relatively weak electron density in this region with no discern-
ible secondary structure (Fig. 4C) [84]. Remarkably, three dimensional
solution NMR data of a RyR2-A construct consisting of residues 10–224
revealed that, in fact, a previously unidentiﬁed α-helix is present
between V95–T104 within the 12-residue insertion of RyR2-A, not ob-
servable in the crystal structure [132]. The NMR data-derived chemical
shift index (CSI) of the RyR2-A construct showed that the structural
motifs as well as their relative locations in solution are identical to
those revealed by the RyR1-A, RyR1-ABC and RyR2-A crystal struc-
tures [83, 84, 86, 132]; however, a clear α-helix in the 95–104 residue
stretch is also indicated by the CSI data [132].
The conservation of position and type of secondary structural
element with available crystal structure data [84] taken together with
the solution data facilitated the calculation of a crystal/NMR hybrid
structure, which shows that the α2 arm helix, only observable by
NMR, exhibits a higher backbone root mean square deviation (rmsd)
compared to the rest of the structural elements (Fig. 4D) [132]. This
higher rmsd is consistent with backbone relaxation measurements
which indicate that the α2 helix undergoes fast internal motions on
the ~ps–ns timescales (i.e. lower 15N–{1H} heteronuclear NOE and
elevated R1) relative to the global fold of the domain; moreover, the
N- and C-terminal sequences ﬂanking the α2 helix appear primarily
responsible for this increased mobility. The NMR data also revealed
chemical exchange on a very slow timescale (i.e. ~ms–s) for many resi-
dues on the face of the RyR2-A crystal/NMR hybrid structure adjacent
to the α2 helix, as peak doubling was apparent in the 1H–15N-HSQC
spectra indicating that those residues readily and stably access multiple
conformations [132].
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Fig. 4. Sequence alignment of the RyR human homologs and relative positions of the α2 helix in the IP3R1-SD and the RyR2-A crystal and crystal/NMR hybrid structures. (A) Multi-se-
quence alignment of the human RyR1 (NCBI accession: P21817.3), RyR2 (Q92736.3) and RyR3 (Q15413.3) domain A regions that include the β4 strand, α1 and α2 helices. RyR1, RyR2
and RyR3 show a very high sequence identity in the region leading up to the 12-residue insertion that is speciﬁc to the RyR2 homolog as well as the region after the insertion. Fully, highly
and partially conserved residues are indicated by ‘*’, ‘:’ and ‘.’, respectively, below the amino acid sequences. The secondary structure elements revealed by the high resolution structures
are indicated above the sequences with the β4 strand colored yellow and the α2 helix which is only NMR-visible colored red. The amino acid ranges are indicated at the left and right of
each respective sequence. Alignment was done in ClustalW. (B) SD structure of IP3R1 solved by X-ray crystallography. This structure (PDB code 1XZZ) shows the arm region composed of
α1 andα2 relative to the position of the β-trefoil. The α2 helix, structurally conserved in the RyR2-A is colored red. (C) RyR2-A structure solved by X-ray crystallography. The α2 helix is
not resolved in the RyR2-A crystal structure (PDB code 3IM5) due to the highmobility. The position of the polypeptide chain that makes upα2 relative to the β-trefoil and theα1 helix is
shownwith the red broken line. (D) RyR2-A structure solved using anX-ray crystallography/NMR hybrid approach (PDB code 2MC2). Theα2 helix, visible only by NMR is colored red. The
β4 strand which is deleted in the delta exon 3 mutant is colored yellow (see also Fig. 1G). The α2 helix rescues the β4 strand in the delta exon 3 mutant via a helix-to-strand structural
transition.
1988 M.-D. Seo et al. / Biochimica et Biophysica Acta 1853 (2015) 1980–19914.5. Effect of disease-associated mutations on RyR2-A dynamics
A particularly remarkable structural transformation occurs in the
RyR2-A harboring a heritable deletion mutation (i.e. delta exon 3)
which causes VT [133]. The RyR2-A delta exon 3 mutant which carries
an N57 to G91 deletion remains fully folded as a β-strand is inserted
into the β-trefoil, thereby rescuing the overall fold (Figs. 1G and 4D)
[85]. Solution NMR data showed that the dynamic α2 arm helix facili-
tates this switch, as CSI data convert from strong positive (i.e. α2-helix)
to negative values (i.e. β4-strand) in the stretch of amino acids responsi-
ble for forming the α2 helix in the wild-type protein [132]. Analysis of
the backbone dynamics of RyR2-A delta exon 3 suggests that the loops
ﬂanking the rescued β4 strand exhibit high mobility on a fast timescale
in contrast to the β4 strand itself which is relatively immobile, consistent
with data showing overall stabilization of delta exon 3 compared towild-
type [85,132].
Interestingly, three HS-loop mutants that cause heritable arrhyth-
mia and tachycardia phenotypes (i.e. P164S, R169Q and R176Q) show
only local structural perturbations conﬁned to the immediate vicinity
of the mutation, by NMR and crystal structure analyses; moreover,
15N–{1H} backbone dynamics measurements are consistent with these
localized effects, as mobility parameters and peak doubling were all
similar to the wild-type domain [132]. These data suggest that since
themutants have conserved overall fold, the dysfunction of the receptor
must occur through perturbed interfaces involved in facilitating channel
gating. Further structural and dynamics assessments are required to
tease out the precise signaling dysfunctions caused by these mutations.5. Concluding remarks
The currently available structural information has signiﬁcantly ad-
vanced our understanding of the relationship between structure and
function of Ca2+ release channels on the ER/SRmembrane. Furthermore,
the utilization of multiple techniques, including X-ray crystallography,NMR spectroscopy and EM, has produced a remarkable synergy in
understanding the mechanisms of IP3R and RyR function. For instance,
the combination of X-ray crystallography and cryo-EM has enabled us
to identify the location of the N-terminal region of RyR1 relative to the
enormous fully-assembled tetrameric channel, thereby revealing the im-
portance of inter-subunit interfaces and providing new insights into the
effects of disease-associated mutations [86,87]. Notably, the docking
models of IP3R1-NT and RyR1-ABC in each cryo-EM map have also re-
vealed structural and functional similarities between these two receptor
channels [78]. Solution NMR spectroscopy has also provided important
new structural information on these receptor channels, not observable
by either X-ray crystallography or EM; further, dynamic properties of
IP3R and RyR domains in solution have also been elucidated by NMR.
Nevertheless, despite marked advances in the structural studies of
IP3Rs and RyRs in the past decade, the high-resolution data are limited
only to the N-terminal regions of IP3Rs and RyRs or the phosphorylation
domain of RyRs. The currently unresolved domains containing the reg-
ulatory region and channel domains comprise the bulk of the channels
(i.e. ~78% for IP3R1 and ~85% for RyR1). In order to fully understand
the integrated regulatory mechanisms of intracellular Ca2+ homeosta-
sis by Ca2+ release channels, the structures of these remaining domains
must be solved at high resolution. Further, these structures must be
used to answer fundamental questions about IP3R and RyR function.
First, where is the bona ﬁde Ca2+-binding sites in IP3R and RyR and
how does Ca2+ binding regulate both IP3R and RyR Ca2+ release activ-
ities in a bell-shaped manner? Although many researchers have inten-
sively investigated the location and function of the Ca2+-binding sites
[134–137], ambiguity and uncertainty remain regarding the true Ca2+
binding sites. Second, how does the N-terminal domain allosterically
regulate the channel domain in the activation mechanisms of IP3R and
RyR? In IP3Rs, the link between structural changes within IP3-binding
N-terminal domain and the channel opening remains unknown. In
RyRs, how do the disease-associated mutations in RyR isoforms perturb
normal channel gating, thereby resulting in dysfunctional skeletal
and cardiac muscle contraction? Third, how is IP3R and RyR gating
1989M.-D. Seo et al. / Biochimica et Biophysica Acta 1853 (2015) 1980–1991distinctively modulated by other cellular signals such as phosphoryla-
tion, ATP binding, protein–protein interaction and oxidative stress?
Elucidating the channel gating mechanisms of both channels in the
context of molecular complexes will provide new insights into the
versatility of Ca2+ signaling. A ﬁnal question is why and how have the
two distinct ER Ca2+ channels, IP3R and RyR emerged in evolution?
Recent genomic analyses have revealed the presence of putative IP3Rs
and RyRs in the unicellular eukaryotes [138–141]. Putative IP3R
homologs have been cloned and functionally characterized in the ciliate
Paramecium and pathogenic unicellular parasites Trypanosomatids
[142–146]. The phylogenetic relationship of IP3Rs and RyRs in eukary-
otes suggests that the divergence occurred along with or shortly before
the emergence of multicellular organisms [147]. Further structural and
functional studies of IP3R/RyR homologs in lower eukaryotes will allow
us to appreciate the rudimentarymechanisms of channel activation and
modulation anddeepen our understanding of the evolutionary aspect of
the Ca2+ signaling tool kit.Acknowledgements
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